Supplemental material
Journal of Medical Economics
Volume 24, 2021 - Issue 1
Open access
1,638
Views
1
CrossRef citations to date
0
Altmetric
Oncology
Reassessing the cost-effectiveness of nivolumab for the treatment of renal cell carcinoma based on mature survival data, updated safety and lower comparator price
Hansoo Kima School of Public Health and Preventive Medicine, Monash University, Melbourne, AustraliaCorrespondence[email protected]
https://orcid.org/0000-0002-3710-8619
Stephen Goodallb Centre for Health Economics Research and Evaluation, University of Technology Sydney, Australia
& Danny Liewa School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia
Pages 893-899
|
Received 16 Jun 2021, Accepted 12 Jul 2021, Published online: 29 Jul 2021
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.